Cargando…

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients

Background: Spinal muscular atrophy type 1 (SMA1) is a devastating genetic disease for which gene-replacement therapy may bring substantial survival and quality of life benefits. Objective: This study investigated the cost-effectiveness of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malone, Daniel C., Dean, Rebecca, Arjunji, Ramesh, Jensen, Ivar, Cyr, Phil, Miller, Beckley, Maru, Benit, Sproule, Douglas M., Feltner, Douglas E., Dabbous, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508058/ https://www.ncbi.nlm.nih.gov/pubmed/31105909 http://dx.doi.org/10.1080/20016689.2019.1601484

Ejemplares similares

Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1
por: Dabbous, Omar, et al.
Publicado: (2019)

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
por: Dean, Rebecca, et al.
Publicado: (2021)

Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy
por: Al‐Zaidy, Samiah, et al.
Publicado: (2018)

Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8
por: Dabbous, Omar, et al.
Publicado: (2019)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever
por: Mahajan, Rajiv
Publicado: (2019)

Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
por: D'Silva, Arlene M., et al.
Publicado: (2022)

Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
por: Mirea, Andrada, et al.
Publicado: (2021)

Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy
por: Kichula, Elizabeth A., et al.
Publicado: (2021)

Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
por: René, Charlotte A., et al.
Publicado: (2023)

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies
por: Pane, Marika, et al.
Publicado: (2023)

Modern x86 assembly language programming: covers x86 64-bit, AVX, AVX2, and AVX-512
por: Kusswurm, Daniel
Publicado: (2018)

Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre Experience
por: Friese, Johannes, et al.
Publicado: (2021)

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
por: Mendell, Jerry R., et al.
Publicado: (2021)

Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
por: Stettner, Georg M., et al.
Publicado: (2023)

Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study
por: Bitetti, Ilaria, et al.
Publicado: (2022)

Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)
por: Ogbonmide, Tolu, et al.
Publicado: (2023)

Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
por: Finkel, Richard S., et al.
Publicado: (2023)

Erratum to: Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment
por: McGrattan, Katlyn E., et al.
Publicado: (2023)

Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment(1)
por: McGrattan, Katlyn E., et al.
Publicado: (2023)

Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports
por: Mizuno, Tomoko, et al.
Publicado: (2023)

Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec—Preliminary Results
por: Soini, Venla, et al.
Publicado: (2023)

Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen-induced arthritis
por: Feuerherm, A. J., et al.
Publicado: (2019)

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
por: Strauss, Kevin A., et al.
Publicado: (2022)

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
por: Strauss, Kevin A., et al.
Publicado: (2022)

Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey
por: Toro, Walter, et al.
Publicado: (2023)

Beginning x64 Assembly Programming: From Novice to AVX Professional
por: Van Hoey, Jo
Publicado: (2019)

High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): Retrospective Analysis of the Kids’ Inpatient Database (KID)
por: Cardenas, Jessica, et al.
Publicado: (2018)

Economic burden of spinal muscular atrophy: an analysis of claims data
por: Belter, Lisa, et al.
Publicado: (2020)

Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy
por: Yang, Min, et al.
Publicado: (2022)

Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
por: Day, John W., et al.
Publicado: (2021)

Modern x86 assembly language programming: 32-bit, 64-bit, SSE, and AVX
por: Kusswurm, Daniel
Publicado: (2014)

Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative?
por: Montes, Jacqueline, et al.
Publicado: (2015)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy
por: Kobayashi, Dione T., et al.
Publicado: (2013)

Tuning the cache memory usage in tomographic reconstruction on standard computers with Advanced Vector eXtensions (AVX)
por: Agulleiro, Jose-Ignacio, et al.
Publicado: (2015)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Cannot write session to /tmp/vufind_sessions/sess_k0hn6nnsnc6cnp8kdli4dblq4d